| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_143ac4fbe1e063c6a828a96cfffc34d5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d91ffd46cc8969b74892d453464e50f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46bee79fcecfe5d2e00db3ee128e28ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45754ad79df0cee87e1ebbd35792fab1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b231376d0a664327cc117fbdc854ca72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca084258c9b9eed1cffd97f67b43294e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1e3474338594845e1d3e379e37db79b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76bbde25cd79e4092195f66e34f094a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6671d75d1900f6aa01bf25f8416e16f |
| publicationDate |
2016-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016030436-A1 |
| titleOfInvention |
Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration |
| abstract |
The formulation for oral administration of the present invention containing Mosapride or its salt is a double layer formulation consisting of a fast-release layer for rapid release of a drug and a sustained-release layer for slow release in order to simultaneously satisfy the rapid exhibition of pharmacological activities and sustained maintenance of pharmacological activities for 24 hours, wherein the high-viscosity hydroxypropyl methylcellulose (HPMC) and the low-viscosity HPMC are used in mixture such that the content of a high viscosity HPMC as a controlled-release matrix within the sustained-release layer has a higher content, thereby capable of controlling the dissolution rate in the regions having different pH values within the gastrointestinal tract and/or the retention time in the gastrointestinal tract. Additionally, the formulation of the present invention is a small-sized preparation with a total weight of 200 mg or less, preferably from 150 mg to 160 mg, thus capable of improving drug compliance of patients. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10588974-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11129897-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110934853-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110934853-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11246852-B2 |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |